Literature DB >> 22282172

Laboratory creation of a highly transmissible H5N1 influenza virus: balancing substantial risks and real benefits.

Andrew T Pavia1.   

Abstract

Controversy erupted when influenza researchers announced that they had created an H5N1 influenza virus that was transmissible between ferrets. The controversy escalated when the National Science Advisory Board for Biosecurity (NSABB) recommended that the work be published but recommended significant voluntary redactions. The responses to the NSABB action and to the research itself have been polarized. A readily transmitted H5N1 virus could be extraordinarily lethal; therefore, the risk for accidental release is significant, and deliberate misuse of the data to create a biological weapon is possible. However, the knowledge gained by these and future experiments under appropriate safeguards is likely to allow critical understanding of influenza transmission and virulence. It would be irresponsible to adopt either extreme solution: to prevent and censor the research or to allow unlimited distribution without careful review by an independent group, such as the NSABB.

Entities:  

Mesh:

Year:  2012        PMID: 22282172     DOI: 10.7326/0003-4819-156-6-201203200-00386

Source DB:  PubMed          Journal:  Ann Intern Med        ISSN: 0003-4819            Impact factor:   25.391


  3 in total

Review 1.  Potential strategies and biosafety protocols used for dual-use research on highly pathogenic influenza viruses.

Authors:  Lanying Du; Ye Li; Jimin Gao; Yusen Zhou; Shibo Jiang
Journal:  Rev Med Virol       Date:  2012-09-14       Impact factor: 6.989

Review 2.  Mammalian-transmissible H5N1 influenza: facts and perspective.

Authors:  Michael T Osterholm; Nicholas S Kelley
Journal:  mBio       Date:  2012-02-24       Impact factor: 7.867

Review 3.  Animal virus discovery: improving animal health, understanding zoonoses, and opportunities for vaccine development.

Authors:  Eric Delwart
Journal:  Curr Opin Virol       Date:  2012-03-15       Impact factor: 7.090

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.